id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-276351-cv5th7hd	Moorlag, Simone J.C.F.M.	Safety and COVID-19 symptoms in individuals recently vaccinated with BCG: a retrospective cohort study	2020-08-05		.txt	text/plain	1279	81	46	BCG vaccination trials for reducing SARS-CoV-2 infection are underway, but concerns have been raised regarding the potential harm of strong innate immune responses. To investigate the safety of BCG vaccination, we retrospectively assessed coronavirus disease 2019 (COVID-19) and related symptoms in three cohorts of healthy volunteers who either received BCG in the last five years or not. In conclusion, recent BCG vaccination is safe and large randomized trials are needed to reveal if BCG reduces the incidence and/or severity of SARS-CoV-2 infection. The incidence of self-reported sickness ( Figure 4B ) as well as the 252 incidence of symptoms ( Figure 4C and D, Figure S6 ) was not significantly different between 253 responders and non-responders, indicating that a strong trained immunity profile is not 254 associated with increased sickness or severity of symptoms during the COVID-19 pandemic. COVID-19: A model correlating BCG vaccination to protection from 696 mortality implicates trained immunity.	./cache/cord-276351-cv5th7hd.txt	./txt/cord-276351-cv5th7hd.txt